Purpose: Coronavirus Disease 2019 (COVID-19) is a rapidly expanding global pandemic and dramatically altered the delivery of reperfusion therapy for patients with ST-segment–elevation myocardial infarction (STEMI). The aim of this study is to analysis role of fibrinolytic therapy in STEMI patients during COVID-19 Pandemic.
Research Methodology: This was a single-centre prospective study in Dr. M. Djamil General Hospital (Padang, Indonesia), with included all patients presenting with suspected COVID 19 with STEMI followed fibrinolytic therapy between 1 April to 30 May 2020 (during COVID-19 pandemic) and compare same periode in 2019. The primary outcome will be in- hospital major adverse cardiovascular events (MACE) defined as as composite of all-cause mortality, stroke, recurrent MI, unstable angina, heart failure, cardiogenic shock and or cardiac arrest. Secondary outcomes were MACE within 3 months follow-up.
Results: A total of 20 patients were included in the final analysis. Mean age was 56.70 ± 8.74 years. Male were 75%, hypertensive 60%, smoker 55%, diabetes mellitus 45%. During the pandemic period from April to May 2020, there was an approximately 64% drop STEMI cases compared to the same period in 2019. There were 15 patients (75%) who had failed. In primary outcome, there is no incidence of in-hospital MACE. Secondary outcomes were reported 2 patient with MACE incidence within 3 months follow-up.
Conclusion: Fibrinolytic therapy is the choice of reperfusion therapy in early COVID-19 pandemic era and relatively still had a good prognosis in case of MACE incidence
Keyword: Fibrinolytic, STEMI, Covid-19

- Journal
- Articles
- Author Center
- Society
Editorial Board
The ESMED Editorial Board is comprised of experts from around the world.
Meet the community
See what our members have been working on.
Membership
Join ESMED for access to member-only content, congress discounts, and more.
- Policy